College Fails To Get More Royalties From Merck Drug

Law360, New York (July 28, 2010, 4:29 PM EDT) -- A federal appeals court has ruled that the University of Illinois tried too late to reverse an arbitrator's unfavorable decision in a dispute with a subsidiary of Merck & Co. over an intellectual property license for a cancer drug.

The U.S. Court of Appeals for the Seventh Circuit on Tuesday ended the university's hopes of squeezing more royalties from Organon Teknika Corp. LLC, which licensed intellectual property from the university to make Tice BCG.

The university's royalties are determined by sales to Organon customers, and the...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.